poster

Aripiprazole 2-Month Ready-to-Use: A Novel Long-Acting Injectable Antipsychotic Formulation for Administration Once Every 2 Months

Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a novel long-acting injectable formulation of aripiprazole monohydrate for gluteal intramuscular administration. In the US, Ari 2MRTU is a...

10/26/2023

Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Study

Positive and Negative Syndrome Scale (PANSS) factor scores (as described by Marder) were assessed in a post hoc analysis of data from adults with acute schizophrenia who received 25-week ...

10/26/2023

Aripiprazole Once-Monthly for the Treatment of Adult Patients in the Earlier Stages of Bipolar I Disorder – a Post Hoc Analysis of Data From a Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Trial

This post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized-withdrawal trial (NCT01567527) was conducted to evaluate the efficacy of aripiprazole once-month...

10/26/2023

"When Perception Deceives: Unmasking Bilateral Occipito-Parietal Infarcts Presenting as Complex Hallucinations and Self-Harm"

Case of a 51-year-old veteran with no prior psychiatric history who presented to the ED with self-inflicted injury and positive symptoms (both CAH, VH), and was transferred to inpatient p...

10/26/2023

“When was your last bowel movement?” A Case Study on Treatment Resistant Constipation in a Patient on Clozapine

This poster is a case study on demonstrating the utility of using Lubiprostone to treat Clozapine-induced treatment resistant constipation.

10/26/2023

52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...

10/26/2023

A case of acute intermittent porphyria attack with psychiatric symptoms in a female resolving with the removal of stressors and lack of medical treatment

This poster addresses a case of a middle-aged female with known acute intermittent porphyria and substance use disorder presenting with psychotic symptoms. During her hospitalization, she...

10/26/2023

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

10/26/2023

A Pilot Study to Assess if Patients With Schizophrenia Can Form a Working Alliance With a Digital Therapeutic

Use of digital therapeutics has increased in recent years, but it is unclear if patients can establish an effective therapeutic digital working alliance (DWA) with digital therapeutic. In...

10/26/2023

A Psychiatric Drug Prescription Framework to Predict Drug-Drug Interaction Risks with Artificial Intelligence

Using AI to streamline complex psychiatric drug prescriptions for more effective and safe clinical prognosis.

10/26/2023

Tracks

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products